Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results

Author:

Avenarius Matthew R.1,Huang Ying2,Hyak Jonathan2ORCID,Byrd John C.3,Bhat Seema A.2,Grever Michael2,Kittai Adam S.2,Rogers Kerry A.2,Jones Dan1ORCID,Zhao Weiqiang1ORCID,Heerema Nyla A.1,Abruzzo Lynne V.1,Woyach Jennifer2,Miller Cecelia R.1ORCID

Affiliation:

1. Department of Pathology College of Medicine The Ohio State University Columbus Ohio USA

2. Division of Hematology Department of Internal Medicine College of Medicine The Ohio State University Columbus Ohio USA

3. Department of Internal Medicine The University of Cincinnati Cincinnati Ohio USA

Abstract

AbstractFluorescence in situ hybridization (FISH) to detect the recurrent cytogenetics abnormalities deletion 13q, trisomy 12, deletion 11q, and deletion 17p is important for prognostication in chronic lymphocytic leukemia (CLL). A subset of patients are negative for each of these abnormalities (normal 12/13/11/17 FISH), and outcomes are heterogenous within this group. To elucidate variables important for prognostication in this subgroup we conducted a retrospective analysis of 280 treatment‐naïve CLL patients with normal standard CLL FISH results. In a multivariable model, advanced Rai stage (p = 0.04, hazard ratio [HR] 1.24 (95% confidence interval [CI] 1.01–1.53)), unmutated immunoglobulin heavy chain gene (IGHV) (p < 0.0001, HR 5.59 (95% CI 3.63–8.62)) and IGH rearrangement by FISH (p = 0.02, HR 2.56 (95% CI 1.20–5.48)) were significantly associated with shorter time to first treatment. In a multivariable model for overall survival, increasing age at 5‐year increments (p < 0.0001, HR 1.55 (95% CI 1.25–1.93)), unmutated IGHV (p = 0.01, HR 5.28 (95% CI 1.52–18.35)) and gain of REL (p = 0.01, HR 4.08 (5% CI 1.45–11.49)) were significantly associated with shorter survival. Our study identifies variables important for refining prognosis for CLL patients with normal standard CLL FISH results.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3